Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Open Access
- 1 June 2010
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 6 (1) , 281-288
Abstract
Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study Takahiko NagamineDivision of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, Japan During treatment of acute-phase schizophrenia, attention needs to be given to physical as well as psychological symptoms. It is often difficult, however, to obtain information on physical symptoms from patients with psychomotor excitation, and only laboratory examinations can provide objective data. The results of laboratory parameters measured in 68 patients with schizophrenia during psychomotor excitation and approximately 1 month later during the medicated recovery phase have been analyzed retrospectively. Abnormal laboratory values during psychomotor excitation were frequent. The most frequent (≥35% of patients) were increased white blood cell count, low serum potassium levels, high levels of fasting blood sugar, lactate dehydrogenase and uric acid. There were fewer abnormal values during the medicated recovery phase. The most frequent (≥25% of patients) were high serum levels of triglycerides, amylase, creatinine kinase, and low-density lipoprotein cholesterol. Abnormal triglyceride levels were found significantly more frequently in patients receiving olanzapine than those receiving risperidone. Abnormal values during the acute phase may be the result of excitation such as increased sympathetic tone and dehydration. Abnormal values during the recovery phase appeared to be related to the adverse metabolic effects of antipsychotic drugs. The frequency of these abnormal values was particularly high in patients receiving olanzapine alone or in combination with other medications.Keywords: schizophrenia, laboratory test values, acute phase, recovery phase, risperidone, olanzapineKeywords
This publication has 12 references indexed in Scilit:
- Pathogenesis and Management of the Dyslipidemia of the Metabolic SyndromeMetabolic Syndrome and Related Disorders, 2009
- Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Schizophrenia Research, 2008
- Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patientsNeuropsychiatric Disease and Treatment, 2008
- Glucose metabolism and catecholaminesCritical Care Medicine, 2007
- Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.2007
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2007
- Serum creatine kinase levels in chronic psychosis patients − a comparison between atypical and conventional antipsychoticsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2006
- Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophrenia Research, 2005
- The Expert Consensus Guideline Series. Treatment of behavioral emergencies.2001
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987